NTLA vs EDIT
NTLA and EDIT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | EDITEDITAS MEDICINE, INC. |
|---|---|---|
| Market cap | $1.75B | $409.29M |
| P/S | 25.8x | 10.1x |
| Revenue growth (YoY) | 16.9% | 25.4% |
| Earnings growth (YoY) | 20.5% | 32.5% |
| EBIT margin | -651.7% | -394.9% |
| ROE | -56.7% | -152.0% |
| 1y total return | +1.6% | -11.2% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: NTLA vs EDIT
| 지표 | NTLA | EDIT |
|---|---|---|
| 최종 가치 | $5.5K | $1.1K |
| 총수익률 | -45.1% | -89.4% |
| CAGR | -5.6% | -19.5% |
| 변동성 | 78.3% | 83.6% |
| 샤프 | 0.26 | 0.09 |
| 소르티노 | 0.39 | 0.14 |
| 최대 낙폭 | -96.5% | -98.9% |
공통 거래일 2600일 기준, 2016-06-29 → 2026-10-30 · 무위험수익률 4.16% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)